In-depth Analysis and Forecast Of The Bladder Cancer Market On The Global As Well As Regional Level 2025
"The
Latest Research Report OpportunityAnalyzer: Bladder Cancer -
Opportunity Analysis and Forecasts to 2025 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About Bladder
Cancer Market
The bladder cancer market in the
seven major pharmaceutical markets (US, France, Germany, Italy,
Spain, UK, and Japan) has remained largely unchanged in the past
10-20 years. However, significant expansion is expected starting in
2016, with the introduction of several new therapies that are
projected to fuel market growth. In addition, bladder cancer has a
robust early-stage pipeline that will contribute to market growth
during the forecast period. Currently, the bladder cancer market is
dominated by generic chemotherapy and immunotherapy. Though initially
effective, toxicity and lack of clinical efficacy in improving
overall survival have left the door open for more tolerable and
effective drugs to be developed. In the past, bladder cancer has not
been an area of focus for pharmaceutical companies, but that is
rapidly changing as more companies focus on the bladder cancer
market, recognizing the high level of unmet need and relatively clear
regulatory path. During the forecast period, the market landscape
will begin to change dramatically with the introduction of newer
immunotherapies, specifically, PD-1 checkpoint modulators, of which
five are expected to launch by 2025. These drugs will provide
much-needed alternatives to bladder cancer patients who have not
benefitted from traditional treatments.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1230660
Key Questions Answered
- How will the bladder cancer
market landscape in the 7MM (US, France, Germany, Italy, Spain, UK,
and Japan) change from 2015-2025?
- What are the most promising
late-stage pipeline drugs in bladder cancer?
- How do the clinical and
commercial attributes of late-stage pipeline therapies compare with
one another, and against existing treatment options?
- What are the unmet needs in
bladder cancer treatment management?
- What drivers and barriers will
affect bladder cancer therapeutics sales in the 7MM over the forecast
period?
Scope
- Overview of bladder cancer,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and current management strategies.
- Topline Bladder cancer market
revenue from 2015-2025. Annual cost of therapy (ACOT) and major
pipeline product sales in this forecast period are included.
- Key topics covered include
current treatment options, unmet needs and opportunities, and the
drivers and barriers affecting bladder cancer therapeutics sales in
the 7MM.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of late-stage pipeline products.
- Analysis of the current and
future market competition in the global bladder cancer therapeutics
market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global bladder
cancer therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the bladder cancer
therapeutics market in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments,
and strategic partnerships.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Bladder Cancer: Executive
Summary 10
2.1 Bladder Cancer Market in the
7MM Expected To Triple in Size From 2015 to 2025 11
2.2 Big Pharma Focuses on Label
Expansion, While Smaller Companies Focus on Developing Drugs with
Novel Mechanisms of Action 12
2.3 The Levels of Unmet Need
Remain High Across Bladder Cancer Settings 13
2.4 Pipeline Agents Will Reduce
Unmet Need, but Opportunities Remain 13
2.5 NMIBC Settings Are Not
Expected to Change Significantly, While PD-1 Checkpoint Inhibitors
Are Expected to Gain Stronghold in Advanced Disease Settings 14
Send
An Enquiry Request @
2.6 What Do Physicians Think? 17
3 Disease Overview 19
3.1 Etiology and Pathophysiology
19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Classification or Staging
Systems 21
3.3 Symptoms 24
3.4 Prognosis 25
3.5 Quality of Life 25
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities
27
4.3 Global Trends 28
4.3.1 Incidence 29
4.3.2 Relative Survival 31
4.4 Forecast Methodology 32
4.4.1 Sources Used Tables 32
4.4.2 Forecast Assumptions and
Methods 36
4.4.3 Sources Not Used 39
4.5 Epidemiological Forecast for
Bladder Cancer (2015-2025) 40
4.5.1 Diagnosed Incident Cases of
Bladder Cancer 40
4.5.2 Age-Specific Diagnosed
Incident Cases of Bladder Cancer 41
4.5.3 Sex-Specific Diagnosed
Incident Cases of Bladder Cancer 43
4.5.4 Age-Standardized Diagnosed
Incidence Rates of Bladder Cancer 44
4.5.5 Diagnosed Incident Cases of
Bladder Cancer by Stage at Diagnosis 45
4.5.6 Five-Year Diagnosed
Prevalent Cases of Bladder Cancer 46
4.6 Discussion 48
4.6.1 Epidemiological Forecast
Insight 48
4.6.2 Limitations of the Analysis
49
4.6.3 Strengths of the Analysis 50
5 Current Treatment Options 51
5.1 Overview 51
5.2 Diagnosis and Treatment 51
5.2.1 Diagnosis 51
5.2.2 Treatment Guidelines and
Leading Prescribed Drugs 53
5.3 Clinical Practice 54
5.4 Product Profiles - Major
Brands, Immunotherapies 56
5.4.1 Bacillus Calmette-Gurin
(BCG) 56
5.4.2 Tecentriq (atezolizumab) 63
5.4.3 Opdivo (nivolumab) 72
5.5 Product Profiles - Major
Brands, Chemotherapies 79
5.5.1 GemCis
(gemcitabine/cisplatin) 79
5.5.2 Mitomycin C 83
5.5.3 Valstar (valrubicin) 84
5.5.4 Javlor (vinflunine
ditartrate) 88
6 Unmet Needs Assessment and
Opportunity Analysis 93
6.1 Overview 93
6.2 Improved Treatments for
Patients with BCG-Relapsed/Refractory NMIBC 93
6.2.1 Unmet Need 93
6.2.2 Gap Analysis 94
6.2.3 Opportunity 94
6.3 Prevention of Disease
Progression in Patients with NMIBC 95
6.3.1 Unmet Need 95
6.3.2 Gap Analysis 95
6.3.3 Opportunity 96
6.4 Therapies for Advanced Disease
Beyond Immune Checkpoint Inhibitors 96
6.4.1 Unmet Need 96
6.4.2 Gap Analysis 97
6.4.3 Opportunity 97
6.5 Predictive Biomarkers to Drive
Drug Discovery 97
6.5.1 Unmet Need 97
6.5.2 Gap Analysis 98
6.5.3 Opportunity 98
6.6 Improved Diagnostic Methods 98
6.6.1 Unmet Need 98
6.6.2 Gap Analysis 99
6.6.3 Opportunity 99
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment